Home / Filing changes / MDT
Free · no account · quoted from the filing
What changed in MDT's 10-K
Source: 10-K filed 2026-06-18 · compared against 10-K 2025-06-20. Every passage below is quoted verbatim from the filing itself.
Segments
This filing
A net cost of $70 million associated with the separation of the Diabetes Business.
Tax
This filing
Our effective tax rate for fiscal year 2026 was 21.2 percent, as compared to 16.6 percent in fiscal year 2025.
Legal
This filing
In September 2025, the Appellate Court remanded the case back to the Tax Court for additional proceedings.
Demand
This filing
Neuromodulation (NM) net sales for fiscal year 2026 increased 7 percent as compared to fiscal year 2025.
Risk
This filing
offset by Pelvic Health and the Pipeline Vantage recall.
Products
This filing
The Stealth AXiS Surgical System received U.S. FDA approval for spinal procedures in February 2026
Risk
This filing
One of the most prevalent attacks on large organizations has been ransomware, which can have a devastating impact on an organization's operations.
What it means — the analyst reading
The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.
See the Filing Change Monitor →Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.